Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes
Background and Aims Although many studies revealed transcriptomic subtypes of HCC, concordance of the subtypes are not fully examined. We aim to examine a consensus of transcriptomic subtypes and correlate them with clinical outcomes. Approach and Results By integrating 16 previously established gen...
Saved in:
Published in | Hepatology (Baltimore, Md.) Vol. 76; no. 6; pp. 1634 - 1648 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.12.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background and Aims
Although many studies revealed transcriptomic subtypes of HCC, concordance of the subtypes are not fully examined. We aim to examine a consensus of transcriptomic subtypes and correlate them with clinical outcomes.
Approach and Results
By integrating 16 previously established genomic signatures for HCC subtypes, we identified five clinically and molecularly distinct consensus subtypes. STM (STeM) is characterized by high stem cell features, vascular invasion, and poor prognosis. CIN (Chromosomal INstability) has moderate stem cell features, but high genomic instability and low immune activity. IMH (IMmune High) is characterized by high immune activity. BCM (Beta‐Catenin with high Male predominance) is characterized by prominent β‐catenin activation, low miRNA expression, hypomethylation, and high sensitivity to sorafenib. DLP (Differentiated and Low Proliferation) is differentiated with high hepatocyte nuclear factor 4A activity. We also developed and validated a robust predictor of consensus subtype with 100 genes and demonstrated that five subtypes were well conserved in patient‐derived xenograft models and cell lines. By analyzing serum proteomic data from the same patients, we further identified potential serum biomarkers that can stratify patients into subtypes.
Conclusions
Five HCC subtypes are correlated with genomic phenotypes and clinical outcomes and highly conserved in preclinical models, providing a framework for selecting the most appropriate models for preclinical studies. |
---|---|
Bibliography: | Funding information Supported, in part, by National Cancer Institute grant R01‐CA237327, P50‐CA217674, the Duncan Cancer Prevention Research Seed Funding Program at MD Anderson Cancer Center (2016 cycle), the MD Anderson Sister Institute Network Fund (2016 and 2019 cycles), and the National Institutes of Health through MD Anderson’s Cancer Center Support Grant P30 CA016672. S.H.L. was supported by the Severance Research Initiative (SRI) project in Yonsei University College of Medicine. Acquisition of blood samples was supported by grant CA165076, the Mayo Clinic Cancer Center (P30‐CA015083), and Mayo Clinic Hepatobiliary SPORE (P50‐CA210964) to L.R.R. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally. Authors’ contributions J-SL conceived and designed the study. SHL, SYY, SHK, BHS, JHS, SG, Q-XL, and J-SL collected, analyzed, and interpreted the data and wrote the manuscript. SHL, SHK, YRC, and J-SL performed the statistical analysis. KJK, JK, and LRR provided study material and clinical data. YSJ, JHS, HJJ, HK, BGL, HGW and SK analyzed the data. JJS, JK, RLJ, AK, YSC, and DAW analyzed and interpreted the data. All authors contributed to the final approval of the manuscript. |
ISSN: | 0270-9139 1527-3350 |
DOI: | 10.1002/hep.32490 |